✦ LIBER ✦

Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation

✍ Scribed by Neil Senzer

Book ID: 114105455
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 79 KB
Volume: 29
Category: Article
ISSN: 0093-7754
DOI: 10.1016/s0093-7754(02)70010-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neurocognitive function in patients with

Neurocognitive function in patients with small cell lung cancer : Effect of prophylactic cranial irradiation

✍ David R. Grosshans; Christina A. Meyers; Pamela K. Allen; Samuel D. Davenport; R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## Abstract ## BACKGROUND. The use of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) has been tempered by fears of detrimental effects on cognitive function. Neuropsychologic testing was prospectively conducted before and after PCI to evaluate its effects on

Prophylactic cranial irradiation in pati

Prophylactic cranial irradiation in patients with small cell lung cancer. A retrospective study of recurrence, survival and morbidity

✍ Ramlov, A.; Tietze, A.; Khalil, A.A.; Knap, M.M. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 260 KB

Pro-gastrin–releasing peptide as a facto

Pro-gastrin–releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation

✍ Kan Yonemori; Minako Sumi; Naoko Fujimoto; Yoshinori Ito; Atsushi Imai; Yoshikaz 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

O-264 A phase III randomized study compa

O-264 A phase III randomized study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small cell lung cancer (NSCLC): a study by the European lung cancer working party

✍ Sculier, Jean-Paul; Lafitte, J.J.; Berghmans, T.; Van Houtte, P.; Lecomte, J.; E 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 179 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB

A randomized phase III study of the doce

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

✍ Athanasios G Pallis; Sophia Agelaki; Athina Agelidou; Ioannis Varthalitis; Kosta 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 359 KB